´ëÇÑ´ç´¢º´ÇÐȸ (¿Â¶óÀÎ) Á¦34Â÷ Ãá°èÇмú´ëȸ ¹× Á¦5Â÷ ÇÑÀÏ´ç´¢º´Æ÷·³ : 2021-05-06±³À°ÀÏÀÚ : 2021-05-06
±³À°Àå¼Ò : ¿Â¶óÀÎ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) Á¦34Â÷ Ãá°èÇмú´ëȸ ¹× Á¦5Â÷ ÇÑÀÏ´ç´¢º´Æ÷·³ ÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ
´ã´çÀÚ : ÀÌ¿¬ÁÖ
¿¬¶ôó : 02-714-9071
À̸ÞÀÏ :
diabetes@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 1300¸í
Èñ¸ÁÆòÁ¡ : 2Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 2 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 130,000¿ø
ºñ°í Àü¹®ÀÇ È¸¿ø 80,000¿ø Àü¹®ÀǺñȸ¿ø 130,000¿ø Àü¹®ÀÇ¿Ü È¸¿ø 50,000¿ø Àü¹®ÀÇ¿Ü ºñȸ¿ø 100,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-06 ¿Â¶óÀÎ 15:00~15:30 DWN12088, a first-in-class PRS inhibitor for the treatment of fibrotic diseases, from lung to liver & kidney fibrosis ¹ÚÁؼ®(´ë¿õÁ¦¾à ½Å¾à¼¾ÅÍ)
±³À°½Ã°£ 05-06 ¿Â¶óÀÎ 15:30~16:00 Angiogenic potential of nano-micellized pro-drug BMP-2 in type I diabetic mice wound healing model À°Á¾ÀÎ(¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ)
±³À°½Ã°£ 05-06 ¿Â¶óÀÎ 16:00~16:30 Development of a noble GPR40 agonist, IDG16177, in the indication of type 2 diabetes mellitus ÃÖ¼º±¸(Àϵ¿Á¦¾à Áß¾Ó¿¬±¸¼Ò)
±³À°½Ã°£ 05-06 ¿Â¶óÀÎ 16:30~17:00 Innovative target discovery platform for metabolic diseases, iClue-TDMD ÃÖö¼ö(°¡ÃµÀÇ´ë ³»°ú)